Booth 2464
Seoul, Korea, Republic of
MEPSGEN is a biotechnology company that develops human microphysiological systems (MPS) also known as organ-on-a-chip and that employs the innovative on-chip products to predict drug toxicity and efficacy more accurately for the rapid and effective translation of new medicines to market.

MEPS-X, the MPS product platform series of MEPSGEN, enables researchers to model human physiology and pathology of key organs at tissue levels. MEPS-TBC, one representative manufactured plastic chip, provides microfluidic spaces designed for modeling tissue-to-tissue barriers with high reproducibility. MEPS-BBB, a model of the human blood-brain barrier built on MEPS-TBC, has been being used by pharmaceutical companies to test drug permeation into the brain, receptor-mediated transcytosis of drug delivery systems, and immune cell trafficking at the BBB while monitoring the barrier function with TEER.

MEPSGEN has the cryopreserved product of MEPS-BBB released for researchers to simply incubate the “ready-to-use” MEPS-BBB and test their drugs with no additional effort to build the model. With more MPS models for brain, liver, kidney, lung, and skin being developed by MEPSGEN, this cryopreserved MPS products will help bring the global market expansion of MPS models as a widely used alternative drug test tool to animal studies in near future.

With the technology, MEPSGEN has nanomedicine pipelines targeting Alzheimer's diseases and brain tumors. One representative nanomedicine MG-PE3 currently in the preclinical phase is a lipid nanoparticle that incorporates apoE for clearing amyloid with no side effect. MG-GTX13 is a nanomedicine that targets glioblastoma and other brain tumors.

MEPSGEN also has developed a new microvortex device that can produce lipid nanoparticles (LNPs) encapsulating mRNAs. This technology will enable more effective incorporation of mRNA with greater encapsulation efficiency and higher productivity.